AML
News
Drug combo holds promise of better AML outcomes
Study suggests that the venetoclax-gilteritinib drug combination “potentially improves response frequency and depth.”
Conference Coverage
‘Extremely exciting’ study results guide MM treatment options
New trial data help inform the tailoring of effective treatment approaches for patients with newly diagnosed multiple myeloma (MM).
Conference Coverage
AGILE: ‘Exciting’ survival results for IDH1-mutated AML
Results show survival that is three times longer for a combination of ivosidenib plus azacitidine versus azacitidine alone in a distinct...
Conference Coverage
Talk early to patients with high-risk AML about end-of-life decisions
With nearly 40% of AML patients unable to take part in their own final code discussions, families struggle to guess what their loved ones would...
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
Conference Coverage
Pediatric cancer survivors at risk for opioid misuse
News
Predicting outcomes in therapy-related AML
Case Reports
Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations
Targeting and monitoring several acute myeloid leukemia mutations sequentially provides insights into optimal treatment plans.
Conference Coverage
Black race linked to poorer survival in AML